Auro Laboratories Limited Overview
Auro Laboratories is a single-site, promoter-controlled Indian micro-cap manufacturing generic active pharmaceutical ingredients from MIDC Tarapur, Maharashtra, with an overwhelming concentration in Metformin Hydrochloride — the first-line oral therapy for type 2 diabetes — which Crisil estimated contributes nearly 80% of revenue. The company holds European Certificates of Suitability (CEPs) for Metformin HCl and Chlorphenamine Maleate, EU-GMP and WHO-GMP accreditation, and exports roughly 70–75% of output to Europe, South-East Asia, the Middle East, Africa and Latin America. Between FY2024 and FY2026 it executed a debt-funded brownfield expansion that shut the legacy unit for about nine months, collapsing FY2025 revenue by roughly 64%, before a partial recovery in FY2026. Management now markets an enlarged metformin capacity, direct-compression granules and a new finished-dose (FDF) tablet line for metformin combinations with gliptins and gliflozins. The equity story is a leveraged volume ramp-up bet: a sharply larger asset base, net debt above INR 600 million, and a sub-scale revenue line that must now catch up.
What the company does. Auro Laboratories manufactures and sells bulk drugs (APIs), pharmaceutical intermediates and, increasingly, value-added downstream forms of its core molecule. Its historical self-description, repeated across its website, exchange profiles and trade-show listings, positions it as an API, intermediates and generic formulations maker founded in Mumbai with a plant at Tarapur about 120 km from the city, whose primary focus is anti-diabetic drugs — specifically Metformin HCl and the sulfonylurea Glibenclamide — complemented by toll/custom manufacturing of APIs and intermediates on a contract basis. In 2026 trade-show profiles (CPHI Milan, CPHI India, CPHI Middle East, CPHI Korea, CPHI South-East Asia) the company describes itself more broadly as a manufacturer of APIs, direct compression (DC) granules and finished dosage forms, citing an expanded metformin capacity and a newly added tablet facility.
Business model. The model is a classic merchant-API business: Auro buys key starting materials and reagents (a material portion imported from overseas vendors per Acuite, April 2026), runs multi-step chemical synthesis and crystallisation at Tarapur, and sells pharmacopoeial-grade API in bulk to generic finished-dose manufacturers who hold the marketing authorisations. Regulatory dossiers (CEPs; country registrations in South Korea, Malaysia, Taiwan, Iran, Egypt and Bangladesh per the company's CPHI China profile) are the commercial "licence to sell" into each market. Value is captured through cost per kilogram, yield, consistency and regulatory acceptability rather than brand.
Revenue model mix. Product sales dominate. Toll/custom manufacturing and "regulatory services" are listed offerings but their revenue share is not publicly disclosed. There is no subscription or licensing revenue. An approximate mix based on available disclosures:
Value-chain position. Upstream of finished-dose generic manufacturers; downstream of commodity chemical suppliers (dimethylamine hydrochloride / dicyandiamide-type inputs for metformin — specific inputs not disclosed by the company). Auro is not backward-integrated into key intermediates, unlike its largest Indian peer Aarti Drugs, which commissioned a dedicated amines facility in FY2026 to self-supply metformin intermediates (Aarti Drugs Q2 and Q3 FY2026 disclosures). The FDF move represents Auro's first meaningful forward integration.
Customer types. Generic formulators in regulated (EU) and semi-regulated/emerging markets; Crisil notes a large client base, and Acuite notes established customers across Europe and South-East Asia. No single-customer concentration figures are publicly disclosed. Credit terms of 60–90 days are extended to major clients (Crisil, Aug 2025).
Independent characterisation. Auro is best understood as a sub-scale, single-product metformin specialist that has just made a capital commitment roughly four times its pre-expansion fixed-asset base (gross PP&E rose from INR 172.8 million in FY2022 to INR 896.7 million in FY2026, S&P data). Its competitive moat rests on regulatory credentials (CEP, EU-GMP via Swissmedic per company profile, WHO-GMP valid to September 2028) rather than scale or cost leadership. The business is a price-taker in a globally commoditised molecule whose market price tracks raw-material costs (Vistin Pharma Q3/Q4 2025 commentary), so the investment case hinges on capacity utilisation and the success of higher-value DC granules and FDF combinations.
Strategy
Stated strategy themes (paraphrased from company profiles and rating rationales; no investor-day or earnings call exists).
-
Anti-diabetic focus: concentrate on the diabetes therapeutic area, which management has long described as among the fastest-growing segments, with metformin as the anchor and additional anti-diabetic molecules "on the anvil."
-
Scale in metformin: expand metformin capacity (brownfield expansion completed 2025) to move from a niche supplier to a meaningful-volume producer.
-
Move up the value chain: add DC granules, combination granules (metformin + gliptins/gliflozins) and a finished-dose tablet facility (1 billion tablets p.a.).
-
Regulated-market credentials: maintain CEPs, EU-GMP (Swissmedic per company profile) and WHO-GMP; extend country registrations.
-
Patent-expiry pipeline: develop new APIs to launch on patent expiry (molecules undisclosed).
-
International marketing: intensive CPHI participation across six regional events in 2026.
Strategic initiatives — last 24 months
Medium-term guidance. Management provides no formal financial guidance. The only forward-looking quantification is Acuite's expectation (April 2026) of net cash accruals of INR 6–15 crore over FY2026–FY2027 against repayment obligations of INR 2–6 crore over the same period.
Products & Services
Because Auro reports one segment, the catalogue is organised by therapeutic/product family. Pricing is not publicly disclosed for any product; for context, QYResearch (Oct 2025) estimates the 2024 average global metformin HCl API price at roughly US$5,894 per MT.
Anti-diabetic franchise (core)
| Product | Description & capabilities | Regulatory credentials | Target customer | Launch / latest status | Notes |
|---|---|---|---|---|---|
| Metformin Hydrochloride API (flagship) | Biguanide; first-line type 2 diabetes therapy. Capacity claims vary: >500 TPA (legacy site text), 1,800 MTPA expanding to 3,600 MTPA (IIFL summary), 1,260 → 2,100 MT p.a. total plant (Acuite, Apr 2026), and 7,200 MT/yr metformin (company CPHI 2026 profiles) | CEP (EDQM) since Sep 2006; EU-GMP; WHO-GMP valid to Sep 2028; USDMF listed by PharmaOffer | Generic tablet makers in EU, SE Asia, Middle East, Africa, LatAm | Expansion completed 2025; new block commissioned Aug 2025 | ~80% of revenue (Crisil). Capacity discrepancy flagged in Section 8 |
| Metformin Direct Compression (DC) Granules | Ready-to-compress metformin granules that let formulators skip wet granulation; higher value-add than plain API | Not publicly disclosed (DC grade dossiers) | Formulators seeking process simplification | Marketed in 2026 CPHI profiles | Competes with Vistin Pharma and Wanbury DC grades |
| Metformin combination granules (with gliptins and gliflozins) | Fixed-dose combination granules pairing metformin with DPP-4 inhibitors ("gliptins") and SGLT2 inhibitors ("gliflozins"); specific molecules not named | — | FDC formulators, esp. India and emerging markets | 2026 (company profiles) | Strategic diversification lever |
| Finished Dosage Forms — Metformin tablets & combinations | New FDF facility, stated capacity 1 billion tablets p.a.; metformin single-agent and combinations with gliptins/gliflozins | — | B2B supply / contract supply; domestic and export | 2026 (company profiles) | First forward integration; revenue not disclosed |
| Glibenclamide (Glyburide) | Second-generation sulfonylurea; listed both as API (website) and intermediate (CPHI) | USDMF listed by PharmaOffer | Generic formulators | Legacy product | Small, undisclosed contribution |
| Glimepiride | Third-generation sulfonylurea | USDMF listed by PharmaOffer | Generic formulators | Listed 2025–2026 | Status of commercial volumes not disclosed |
| Glipizide | Second-generation sulfonylurea | USDMF listed by PharmaOffer | Generic formulators | Listed 2025–2026 | Status of commercial volumes not disclosed |
Non-diabetic APIs
| Product | Description | Credentials | Target customer | Status |
|---|---|---|---|---|
| Chlorphenamine (Chlorpheniramine) Maleate | First-generation antihistamine used in cold/allergy combinations | CEP (EDQM) | OTC and cough/cold formulators | Key secondary product |
| Chlorzoxazone | Centrally acting muscle relaxant | Written confirmation (WC) listed by PharmaOffer | Analgesic/muscle relaxant formulators | Key secondary product (Screener lists as key API) |
| Desmopressin; Octreotide | Peptide APIs listed with CEP on PharmaOffer | possibly a directory error or traded products | — | — |
| Other listed molecules | Diuretic, iron-deficiency, antifungal, anti-ulcer, antimalarial, anti-inflammatory, analgesic, antacid APIs; potassium iodide and sodium iodide; microcrystalline cellulose (excipient) | — | Various | Listed by Simply Wall St description |
Services
| Service | Description | Status |
|---|---|---|
| Toll / custom manufacturing (CDMO) | Contract manufacture of APIs and intermediates using Auro's reactors | Long-standing offering; revenue not disclosed |
| Regulatory services | Dossier support for customers' registrations | Listed on PharmaSource directory; revenue not disclosed |
| Pipeline APIs "on patent expiry" | New products under development to be offered when patents lapse | Named molecules not disclosed (CPHI China profile) |
Financial Narrative
Basis: S&P Global Market Intelligence standardised standalone data (StockAnalysis.com, updated 14 Aug 2026), INR million, FY ending 31 March. EBITDA = operating income + depreciation & amortisation (analyst computation). EPS computed on ~6.233 million shares (matches reported FY2025 EPS of INR 2.95 and FY2026 EPS of INR 5.67 per Screener/Fyers).
Margins and growth
Revenue CAGR FY2022–FY2026 (4 years): -11.8% per year. Revenue at FY2026 (INR 307.4 million) remains ~43% below the FY2024 peak (INR 536.35 million).
Commentary — income statement. Three regimes are visible. FY2022–FY2023 was a stable, low-margin commodity phase: revenue ~INR 510–530 million with EBITDA margins of 8–9%, squeezed by freight and raw-material inflation that Crisil notes could not be passed through promptly (operating margins volatile in a 10–23% band through FY2025). FY2024 was an inflection: gross margin jumped to ~50% on softer input costs, foreign-exchange gains of INR 14.3 million, and better realisations, lifting net income to a record INR 77.9 million (PAT margin 14.5%). FY2025 was the expansion trough: the legacy unit was shut for about nine months to integrate with the new block (Crisil; Acuite), cutting revenue 64% to INR 191 million; profitability held up better than revenue because cost of revenue fell proportionately and other income (INR 7.8 million) cushioned the bottom line. FY2026 is the early ramp: revenue recovered 61% to INR 307 million and operating margin reached 24%, but Acuite notes 9MFY2026 revenue of INR 22.25 crore was below expectations owing to Middle East geopolitical disruption. Interest expense quadrupled to INR 39.6 million as capitalisation of borrowing costs ceased post-commissioning, and depreciation rose 2.6× to INR 28.1 million — together absorbing ~65% of the EBITDA gain.
Data-quality flag (FY2026 gross margin). A 79% gross margin is anomalous for a merchant-API business; the S&P cost-of-revenue line (INR 63.3 million) appears to exclude inventory build (inventory rose INR 98.7 million in FY2026) or classify certain manufacturing costs in "other operating expenses" (INR 69.6 million). EBITDA margin (33%) aligns with Acuite's ~31% 9MFY2026 operating margin, so EBITDA is the more reliable profitability measure.
Quarterly trajectory (INR crore; standalone)
Sources: Business Standard/Capital Market for Q1FY25, Q2FY25, Q1FY26, Q2FY26 sales and all net profits; Q3FY25, Q4FY25, Q3FY26, Q4FY26 and Q1FY27 revenues are analyst derivations (from reported YoY growth, net-margin disclosures on Bajaj Broking, and annual totals) and should be verified against Regulation 33 filings. Discrepancies: (a) FY2025 quarterly net profits sum to INR 1.55 crore versus the audited annual PAT of INR 1.84 crore — likely Q4 adjustments or restatement; (b) ScanX reported a Q2 FY2026 "loss of INR 71.58 lakh," conflicting with Business Standard, HDFC Sky and Bajaj Broking, which all show a profit of INR 0.72 crore; the profit figure is adopted as the majority-source reading; (c) Q1 FY2025 revenue is INR 5.72 crore (Business Standard) versus INR 5.92 crore (INDmoney). Q2 FY2026 operating margin was 26.58% (vs. 23.23% in Q2 FY2025).
Run-rate observation. The last four reported quarters (Q2FY26–Q1FY27) imply TTM revenue of ~INR 36.7 crore and TTM PAT of ~INR 4.69 crore. Quarterly revenue has plateaued in an INR 8.8–9.7 crore band for four consecutive quarters — roughly INR 35–39 crore annualised, still ~30% below FY2024's INR 53.6 crore despite a materially larger plant.
Balance sheet
Commentary — balance sheet. The balance sheet has been transformed from a lightly geared trading-style profile (FY2023 debt/equity 0.19×, INR 124 million of liquid assets in FY2022) to a leveraged manufacturing platform. Land was acquired in FY2024 (land line rose from INR 0.44 million to INR 103.19 million), buildings rose five-fold to INR 225 million in FY2026, and machinery rose from ~INR 213 million to INR 562 million on capitalisation of the new block. Debt has been the dominant funding source — total debt rose ~10× from FY2023 to FY2026 while equity rose only ~36% (entirely from retained earnings). Fund-based working-capital limits were near-fully utilised (Crisil). Working capital turned negative in FY2025 and is only marginally positive in FY2026; Crisil assessed liquidity as "stretched" in August 2025, while Acuite (April 2026) termed it "adequate," a divergence that reflects timing and the larger sanctioned limits.
Cash flow
Commentary — cash flow. Cumulative FY2022–FY2026 free cash flow is approximately -INR 1,026 million, funded by ~INR 602 million of net new debt, the FY2022 liquid-asset cushion, and an unexplained INR 419.9 million "sale of property, plant & equipment" line in FY2026. That FY2026 inflow is not explained in any disclosure reviewed; it may represent a reclassification of capital work-in-progress, a capital subsidy, or a sale-and-leaseback, and is the single most important item to verify in the FY2026 annual report. Net of it, FY2026 investing outflow was INR 147.9 million. Operating cash flow deteriorated to INR 21.1 million in FY2026 because inventory was rebuilt by INR 98.7 million to feed the new capacity. No dividends have been paid in five years despite profits (Screener flags this).
Ratios
FY2026 DIO and CCC are distorted by the anomalous cost-of-revenue classification noted in 6.2 and are not economically meaningful; on a revenue basis FY2026 inventory equals ~161 days of sales. Rating-agency equivalents: Crisil/Acuite report adjusted debt/net worth of 1.05× (FY2025) vs. 0.63× (FY2024), and PBDIT/interest of 3.75× (FY2025) vs. 16.55× (FY2024); Crisil reports gross current assets of 400–405 days at 31 March 2025 vs. ~195 days a year earlier, with receivables of 175–180 days and inventory of 85–90 days. Screener showed debtor days of 177 for FY2025.
Commentary — ratios. Every capital-efficiency metric peaked in FY2024 and has since deteriorated as the asset base outran revenue. Asset turnover has collapsed from ~0.9× to 0.25×; at FY2024's ~0.63× asset-turnover-on-enlarged-base, the plant would need to generate ~INR 760 million of revenue — about 2.5× FY2026 — to restore historical efficiency. Interest coverage below 2× and net debt/EBITDA of ~6× in FY2026 leave little margin for a further revenue miss; Crisil's own downgrade trigger was net cash accruals to repayment at or below 1.1×.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment revenue — Bulk drugs/Pharma (INR Mn) | 508.66 | 528.94 | 536.35 | 191.24 | 307.40 |
Segment operating income (INR Mn) | 36.08 | 33.19 | 95.78 | 20.33 | 73.99 |
Segment pre-tax income excl. unusual items (INR Mn) | 38.28 | 34.46 | 103.46 | 18.81 | 51.56 |
Segment operating margin (%) | 7.1 | 6.3 | 17.9 | 10.6 | 24.1 |
Revenue YoY growth (%) | -6.24 | 3.99 | 1.40 | -64.34 | 60.74 |
Contribution to total revenue (%) | 100 | 100 | 100 | 100 | 100 |
Product Group Details
| Product group | FY2025 indicative share of revenue (%) |
|---|---|
Metformin HCl | 80 |
All other APIs and services | 20 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (INR Mn) | 508.66 | 528.94 | 536.35 | 191.24 | 307.40 |
Cost of revenue (INR Mn) | 335.46 | 360.69 | 269.49 | 92.82 | 63.29 |
Gross profit (INR Mn) | 173.19 | 168.26 | 266.86 | 98.42 | 244.11 |
SG&A (INR Mn) | 62.40 | 47.21 | 51.44 | 28.74 | 72.40 |
Operating income (INR Mn) | 36.08 | 33.19 | 95.78 | 20.33 | 73.99 |
Depreciation & amortisation (INR Mn) | 10.17 | 10.74 | 10.92 | 10.96 | 28.10 |
EBITDA (INR Mn) | 46.25 | 43.93 | 106.70 | 31.29 | 102.09 |
Interest expense (INR Mn) | 5.49 | 7.30 | 6.69 | 10.01 | 39.63 |
Pre-tax income excl. unusual items (INR Mn) | 38.28 | 34.46 | 103.46 | 18.81 | 51.56 |
Pre-tax income reported (INR Mn) | 38.28 | 34.46 | 103.46 | 18.81 | 48.09 |
Net income (INR Mn) | 28.45 | 24.42 | 77.92 | 18.39 | 35.33 |
EPS basic (INR) | 4.56 | 3.92 | 12.50 | 2.95 | 5.67 |
EPS diluted (INR) | 4.56 | 3.92 | 12.50 | 2.95 | 5.67 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 34.0 | 31.8 | 49.8 | 51.5 | 79.4 |
Operating margin (%) | 7.1 | 6.3 | 17.9 | 10.6 | 24.1 |
EBITDA margin (%) | 9.1 | 8.3 | 19.9 | 16.4 | 33.2 |
Net margin (%) | 5.6 | 4.6 | 14.5 | 9.6 | 11.5 |
Revenue growth YoY (%) | -6.24 | 3.99 | 1.40 | -64.34 | 60.74 |
Net income growth YoY (%) | -60.38 | -14.15 | 219.09 | -76.40 | 92.14 |
Income Statement
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 5.72 | 3.10 | 3.07 | 7.51 | 2.77 | 8.84 | 9.39 | 9.74 | 8.77 |
Net profit (INR Cr) | 0.75 | 0.36 | 0.05 | 0.39 | -0.11 | 0.72 | 1.95 | 0.97 | 1.05 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Mn) | 549.60 | 559.94 | 857.33 | 990.96 | 1,211.00 |
Cash & short-term investments (INR Mn) | 123.96 | 17.87 | 9.92 | 0 | 13.67 |
Short-term debt incl. current LTD (INR Mn) | 121.15 | 44.00 | 78.66 | 119.29 | 199.91 |
Long-term debt (INR Mn) | 16.62 | 20.13 | 183.78 | 330.85 | 433.14 |
Total debt (INR Mn) | 137.78 | 64.13 | 262.44 | 450.14 | 633.05 |
Net debt (INR Mn) | 13.82 | 46.26 | 252.52 | 450.14 | 619.38 |
Shareholders' equity (INR Mn) | 315.21 | 342.01 | 419.59 | 429.68 | 463.48 |
Goodwill & intangibles (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Working capital (INR Mn) | 174.98 | 175.31 | 69.19 | -7.73 | 22.10 |
Net PP&E (INR Mn) | 172.83 | 202.83 | 548.31 | 775.34 | 896.68 |
Construction in progress (INR Mn) | 36.75 | 76.68 | 326.81 | 564.75 | 144.84 |
Inventory (INR Mn) | 42.55 | 117.56 | 82.40 | 36.68 | 135.40 |
Trade receivables (INR Mn) | 136.13 | 124.05 | 133.92 | 93.93 | 91.51 |
Book value per share (INR) | 50.58 | 54.87 | 67.32 | 68.94 | 74.36 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Mn) | -65.90 | 32.81 | 188.07 | 50.20 | 21.13 |
Capital expenditure (INR Mn) | 46.10 | 40.74 | 356.40 | 238.01 | 571.39 |
Free cash flow (INR Mn) | -112.00 | -7.93 | -168.33 | -187.81 | -550.26 |
Proceeds from asset sales (INR Mn) | 0 | 0 | 0 | 0.02 | 419.91 |
Net debt issued (INR Mn) | 106.19 | -73.64 | 198.31 | 187.71 | 182.91 |
Dividends paid (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Cash interest paid (INR Mn) | 8.26 | 7.30 | 6.69 | 10.01 | 39.63 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing equity (%) | 9.0 | 7.1 | 18.6 | 4.3 | 7.6 |
ROA on closing assets (%) | 5.2 | 4.4 | 9.1 | 1.9 | 2.9 |
ROIC — NOPAT at 25% tax / (equity + net debt) (%) | 8.2 | 6.4 | 10.7 | 1.7 | 5.1 |
Current ratio (x) | 1.87 | 1.97 | 1.29 | 0.96 | 1.08 |
Debt / equity (x) | 0.44 | 0.19 | 0.63 | 1.05 | 1.37 |
Net debt / EBITDA (x) | 0.30 | 1.05 | 2.37 | 14.39 | 6.07 |
Interest coverage — EBIT / interest (x) | 6.57 | 4.55 | 14.32 | 2.03 | 1.87 |
Asset turnover (x) | 0.93 | 0.94 | 0.63 | 0.19 | 0.25 |
Days sales outstanding (days) | 97.7 | 85.6 | 91.1 | 179.3 | 108.7 |
Days inventory outstanding on COGS (days) | 46.3 | 119.0 | 111.6 | 144.2 | 780.9 |
Days payables outstanding on COGS (days) | 52.9 | 116.2 | 84.0 | 244.3 | 269.7 |
Cash conversion cycle (days) | 91.1 | 88.4 | 118.7 | 79.2 | 619.9 |
Region (FY2025 Indicative) Overview
| Region (FY2025 indicative) | Share of revenue (%) | Implied revenue (INR Cr) |
|---|---|---|
Exports (all regions) | 72.5 | 14.07 |
India (domestic) | 27.5 | 5.33 |
Valuation Snapshot
| Metric | Value | Source / date |
|---|---|---|
Last close | INR 231.60 | StockAnalysis, 19 Oct 2026 |
52-week high / low | INR 317 / INR 159 | Screener.in (2026) |
1-year return | +3% (Screener CAGR table) / +5.96% (ScanX) | 2026 snapshots — dates differ |
6-month return | -12.64% | ScanX, Oct 2026 |
3-year price CAGR | 40% | Screener.in |
5-year price CAGR | 20% | Screener.in |
10-year price CAGR | 28% | Screener.in |
Long-run reference | Promoter purchases at INR 5.80 (17 Dec 2013) | Trendlyne |
Liquidity | Thin — e.g., 479 shares traded in a session (Nirmal Bang); 1,370 shares (MarketsMojo) | Various 2025–2026 |
Analyst coverage | 0 analysts | Simply Wall St |
Valuation Multiples
| Multiple | Auro Laboratories | Basis |
|---|---|---|
Market cap (INR Mn) | 1,444 | 6.233 M shares |
Enterprise value (INR Mn) | 2,063 |
|
P/E — TTM (x) | 30.8 | TTM EPS INR 7.52 (Q2FY26–Q1FY27 PAT INR 4.69 cr) |
P/E — FY2026 (x) | 40.8 | EPS INR 5.67 |
P/B (x) | 3.11 | BVPS INR 74.36 (Mar 2026) |
EV/EBITDA — FY2026 (x) | 20.2 | EBITDA INR 102.1 M |
EV/Sales — FY2026 (x) | 6.7 | Revenue INR 307.4 M |
EV/Sales — TTM (x) | 5.6 | TTM revenue ~INR 367 M (derived) |
Dividend yield (%) | 0 | No dividends |
Capital Markets
| Item | Status |
|---|---|
Dividend history (FY2022–FY2026) | Nil every year |
Dividend policy | Not publicly disclosed (not mandatory below top-1,000 threshold) |
Moody's / S&P / Fitch | Not rated |
Domestic rating | Acuite BB+/Stable (LT) and A4+ (ST), Apr 2026; Crisil BB+/A4+ withdrawn Aug 2025 |
Debt maturity profile | Term loan from Indian Bank maturing 30 Sep 2032 (INR 31.90 crore as of Aug 2025); current portion of LTD INR 19.6 M at Mar 2026; Acuite projects repayments of INR 2–6 crore/yr in FY2026–FY2027; short-term working-capital lines INR 180.3 M (Mar 2026) roll annually |
Analyst Conclusions
Management guidance. None issued; no earnings calls or investor presentations. The only third-party forward view is Acuite's expectation of INR 6–15 crore of annual cash accruals over FY2026–FY2027 against INR 2–6 crore of repayments.
Consensus. No sell-side coverage (0 analysts); no consensus estimates exist.
Bull case
-
Operating leverage on a built plant: with capex largely complete (CWIP down to INR 145 M), each incremental rupee of revenue carries ~30%+ EBITDA margins (Q2–Q3 FY2026 evidence); returning only to FY2024 revenue of INR 53.6 crore would roughly double EBITDA and cut net debt/EBITDA toward ~3×.
-
Mix upgrade: DC granules, metformin–gliptin/gliflozin combinations and a 1 bn-tablet FDF line move Auro from commodity API toward higher-value, stickier products, at a time when DPP-4/SGLT2 generics are proliferating.
-
Credential moat at micro-cap scale: CEPs, EU-GMP and WHO-GMP (renewed to 2028) are hard for new entrants to replicate and give access to regulated customers who multi-source.
Bear case
-
Revenue plateau and price deflation: quarterly revenue has stalled at ~INR 9–10 crore for four quarters while global metformin prices softened (Vistin), and Aarti/Wanbury are expanding volume and integration — Auro may be filling capacity only at lower prices.
-
Balance-sheet fragility: EBIT/interest <2×, net debt/EBITDA ~6×, fully utilised working-capital lines and 400-day gross current assets leave little cushion; a further shortfall could trigger a downgrade below BB+.
-
Disclosure and governance gaps: unexplained INR 419.9 M FY2026 asset-sale inflow, mid-term auditor change and a CFO exit, combined with no investor communication, raise the evidentiary bar for the ramp-up thesis; at ~31× TTM earnings and ~3× book, the stock already discounts success.
Key catalysts and monitorables (next 12 months)
Analyst verdict. Auro Laboratories is a credible but under-scaled metformin specialist that has bet its balance sheet on growing into a plant several times larger than the business it replaced. The evidence since commissioning is mixed. On the positive side, the new block is clearly more profitable: operating margins in the high-20s to low-30s percent through FY2026 compare with single digits before the expansion, the company returned to profitability within a quarter of start-up, and it has kept its regulatory licences intact, renewing WHO-GMP through 2028. Promoters hold just over half the equity with no pledges, and the sole lender has enlarged rather than curtailed facilities.
The difficulty is that revenue has not followed capacity. Four consecutive quarters at roughly INR 9–10 crore annualise to well under FY2024's INR 53.6 crore, while interest and depreciation have absorbed most of the EBITDA uplift and pushed coverage below 2×. Working capital remains extremely heavy, and the competitive backdrop has hardened: the category leader has internalised its key intermediate, a mid-size peer is winning US FDA and Middle East metformin business, and global prices have eased. Against this, the market values the company at roughly 31× trailing earnings and 20× FY2026 EBITDA — multiples that already assume a successful ramp.
Our synthesis is therefore "show me." The equity can work if quarterly revenue moves decisively into the mid-teens of crores with margins held, which would roughly halve leverage within two years and validate the FDF and granule strategy. Until then, the risk-reward is skewed by balance-sheet fragility, single-molecule exposure, illiquidity, and unresolved disclosure questions — chiefly the unexplained FY2026 asset-sale inflow and the vacant CFO role. Investors should anchor on the Q2 and Q3 FY2027 prints and the FY2026 annual report notes before underwriting the capacity story. This is an assessment of public information, not investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / appointment | Background | FY2025 total compensation |
|---|---|---|---|---|
Sharat Deorah (DIN 00230784) | Chairman & Managing Director; Promoter | Promoter-director since founding; re-appointed CMD at 35th AGM (28 Jun 2024) | ~Three decades in pharma/API (Crisil; Acuite) | — |
Siddhartha Deorah (DIN 00230796) | Whole-Time Director; Promoter | With company since 1 Aug 1999; re-appointed WTD 28 Jun 2024; retires by rotation & re-appointed at 36th AGM | Director of related entities Auro Impex Pvt Ltd, Auro Real Estate Pvt Ltd (AR 2009-10); signs most exchange filings | — |
Kiran Kulkarni | Whole-Time Director | Re-appointed for 3 years (30 Jun 2026) | Not publicly disclosed (likely plant/technical) | — |
Goverdhandas Aggarwal | Independent Director (as of Mar 2023) | On board since at least 2009-10 | — | Sitting fees — not disclosed |
Kailash Chandra Bubna | Independent Director (as of Mar 2023); historic Audit Committee Chair | On board since at least 2009-10 | — | Sitting fees — not disclosed |
Kavita Vijayakant Sharma | Non-Executive Independent Director | Since 27 Mar 2015; second term 11 Feb 2026–10 Feb 2031 | 10+ years in marketing | Sitting fees — not disclosed |
Vishal Kailash Chandra Jhunjhunwala | Independent Director (as of Mar 2023) | — | — | Sitting fees — not disclosed |
Padma Tapariya | Company Secretary & Compliance Officer | From 1 Oct 2025 | Associate member ICSI; ~7 years' experience | — |
Chief Financial Officer | Vacated | Previous CFO resigned effective 28 May 2026; successor not identified in sources reviewed | — | — |
“—” = not publicly disclosed.
Governance Overview
| Attribute | Status |
|---|---|
Board size | ~7 (3 executive, ~4 independent as of Mar 2023); current composition after 2024–2026 changes not fully verified |
Chair/CEO separation | No — Sharat Deorah is both Chairman and MD |
Independent directors | ~4 of 7 (≥50%, meeting SEBI requirement where chair is executive) |
Women on board | 1 (Kavita Sharma) |
Committees | Audit Committee (historically chaired by K.C. |
Long-tenured independents | Two independents appear on the 2009-10 board and were still listed in 2023; under the Companies Act 2013, IDs are limited to two consecutive five-year terms from 2014. Current status should be checked against the FY2026 annual report |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
28 Jun 2024 | CMD and WTD re-appointments approved | Routine renewal |
14 Aug 2025 | Company Secretary resignation disclosed | Replaced by Padma Tapariya, 1 Oct 2025 |
23 Aug 2025 | Statutory auditor resignation; new auditor | Outgoing auditor cited pre-occupation; confirmed no disagreements with management |
28 May 2026 | CFO resignation | Occurred the day before FY2026 results approval; successor not disclosed — a governance monitorable |
30 Jun 2026 | Kiran Kulkarni re-appointed WTD (3 years) | Continuity of technical leadership |
Major Shareholders
| Holder | Category | Shares | Stake (%) |
|---|---|---|---|
Auro Impex Private Ltd | Promoter group | 1,168,781 | 18.75 |
Sharat Deorah | Promoter | 1,165,800 | 18.71 |
Siddhartha Deorah | Promoter group | 441,650 | 7.09 |
Samridhi Deorah | Promoter group | 241,191 | 3.87 |
Sharat Deorah HUF | Promoter group | 229,029 | 3.67 |
Kirtilaben Jayantilal Mehta | Public | 195,000 | 3.13 |
Samir Jitendra Javeri | Public | 161,533 | 2.59 |
Shikha Lohia | Public | 96,126 | 1.54 |
Ravi Parimal Shah | Public | 90,571 | 1.45 |
Siddhartha Deorah HUF | Promoter group | 5,456 | 0.09 |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Scale / positioning | Data status |
|---|---|---|---|
Aarti Drugs Ltd (India) | Metformin HCl API (major global producer); backward-integrated into amines | FY2026 consolidated revenue INR 2,567.7 crore; PAT INR 194.9 crore | Verified (company/FilingReader, May 2026) |
Wanbury Ltd (India) | Metformin HCl & Metformin DC API (core product alongside sertraline) | FY2026 revenue INR 650.3 crore; EBITDA INR 107.7 crore; PAT INR 66.1 crore | Verified (DSIJ/Sahi, 2026) |
Vistin Pharma ASA (Norway) | Pure-play premium metformin API incl. DC grades | 2025 revenue NOK 452 million; EBITDA NOK 115 million; ~6,000 MT annualised production | Verified (company release Feb 2026) |
Granules India Ltd (India) | Metformin API and FDF (high-volume molecules) | — | — |
Harman Finochem Ltd (India) | Metformin and anti-diabetic APIs | Unlisted; figures not publicly disclosed | — |
USV Pvt Ltd (India) | Metformin API and diabetes formulations (integrated) | Unlisted; figures not publicly disclosed | — |
Shouguang Fukang Pharmaceutical (China) | Large-volume metformin API | — | — |
Chinese metformin producers (multiple) | Cost-leading volume supply | Coherent MI notes heavy global dependence on China/India API supply | Qualitative |
Supriya Lifescience Ltd (India) | Chlorpheniramine maleate API | — | — |
Indian domestic diabetes FDF makers (various) | Metformin + gliptin/gliflozin combination tablets | Fragmented; highly competitive | Qualitative |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Auro Laboratories (FY2026) | Aarti Drugs (FY2026) | Wanbury (FY2026) | Vistin Pharma (CY2025) |
|---|---|---|---|---|
Revenue (local currency) | INR 30.74 cr | INR 2,567.7 cr | INR 650.3 cr | NOK 452 M |
Revenue growth YoY (%) | 60.7 | 7 | 8.5 | 5 |
EBITDA margin (%) | 33.2 | 12.1 | 16.6 | 25.4 |
Net margin (%) | 11.5 | 7.6 | 10.2 | 16.5 |
Balance sheet | Net debt ~INR 62 cr; D/E 1.37× | — | Refinanced Jun 2026 (sub-10% cost) | Net cash NOK 16 M; equity ratio 75% |
Recent Developments
Industry-context developments affecting Auro: * Aarti Drugs commissioned its Sayakha amines facility (Sep 2025) to self-supply metformin intermediates, reaching 1,000 tonnes/month in March 2026; Wanbury received nine US FDA "No DMF Deficiency" letters for Metformin HCl in July–August 2026 and commercialised Metformin DC in Saudi Arabia; Vistin Pharma reported record 2025 volumes but lower global metformin prices. Each intensifies competition in Auro's core molecule.



